HD P023
Alternative Names: HD-P023Latest Information Update: 23 Apr 2024
At a glance
- Originator Handok Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 02 Apr 2024 Preclinical trials in Unspecified in South Korea (PO)
- 02 Apr 2024 Handok plans a phase I pharmacokinetics trial in healthy individuals in April 2024 (NCT06339788)